52 Week Range
As of on the Euronext Paris ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Sanofi says the CHMP adopted a positive opinion for Dupixent
CHMP Recommends Approval Of Dupixent For Severe Chronic Rhinosinusitis With Nasal Polyposis
Abbott And Sanofi Partner To Integrate Glucose Sensing And Insulin Delivery Technologies
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
Biotechnology & Drugs
54 rue la Boetie
Independent Chairman of the Board
Chief Executive Officer, Member of the Executive Committee
Jean-Baptiste Chasseloup de Chatillon
Chief Financial Officer, Executive Vice President, Member of the Executive Committee
Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee
Executive Vice President of Human Resources, Member of the Executive Committee
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.
A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)
A federal judge in New Orleans has rejected Sanofi SA's bid to exclude two expert witnesses retained by plaintiffs to help prove their claims in thousands of lawsuits that its cancer treatment Taxotere caused them to suffer permanent hair loss.
A federal judge has rejected a bid by patients who allege Sanofi SA's cancer treatment Taxotere caused their permanent hair loss to prevent the drugmaker from presenting expert testimony based on an ex-employee's new analysis that showed minimal such side effects.
A federal appeals court on Wednesday delivered a double dose of good news to Sanofi-Aventis U.S., affirming the validity of its first patent on the prostate-cancer drug Jevtana and overturning a ruling against a later patent on a method of administering it.
A federal appeals court has upheld the dismissal of a Utah woman's lawsuit accusing Sanofi SA of failing to warn about the risks its infertility drug Clomid posed to fetuses when taken during pregnancy.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.
Sanofi <SASY.PA> has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.
Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.
French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.
French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.
French drugs and healthcare group Sanofi <SASY.PA> said on Tuesday it had signed a rights deal with Roche <ROG.S> for the 'Tamiflu' product in the United States.
South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.
South Africa's Biovac Institute will start local production of Sanofi's Hexavalent vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.
Mylan Plc is urging a federal judge to reject rival drugmaker Sanofi SA's claims the company engaged in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a political firestorm over price increases.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, the companies said on Wednesday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.